Detalhe da pesquisa
1.
SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
J Virol
; 98(2): e0154623, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299865
2.
Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
J Biomed Sci
; 29(1): 37, 2022 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681239
3.
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
Int J Mol Sci
; 23(9)2022 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35563292
4.
Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice.
J Biomed Sci
; 27(1): 51, 2020 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32290844
5.
Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters.
Mol Ther Methods Clin Dev
; 32(1): 101169, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187094
6.
A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.
Arch Virol
; 158(7): 1523-31, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23456422
7.
Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types.
NPJ Vaccines
; 8(1): 82, 2023 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37268688
8.
Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants.
JCI Insight
; 7(8)2022 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35290246
9.
A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment.
Biomedicines
; 9(7)2021 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34356870
10.
Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses.
Front Immunol
; 12: 751883, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34707615
11.
Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
Front Immunol
; 11: 546, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32300346
12.
Delivery of Antigen to CD8+ Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity.
Front Immunol
; 10: 1839, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428106
13.
Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Front Immunol
; 9: 822, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29755461
14.
Modulation of Epstein-Barr virus latent membrane protein 1 activity by intrabodies.
Intervirology
; 50(4): 254-63, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17460414
15.
Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice.
Vaccine
; 34(8): 1054-61, 2016 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26776472
16.
Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.
Sci Rep
; 6: 30648, 2016 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27470096
17.
Characterization of a monoclonal antibody specific to the Gag protein of porcine endogenous retrovirus and its application in detecting the virus infection.
Virus Res
; 108(1-2): 139-48, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15681064
18.
The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
PLoS One
; 10(12): e0145717, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26714037
19.
Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity.
Vaccine
; 32(12): 1346-53, 2014 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486311
20.
Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement.
PLoS Negl Trop Dis
; 7(9): e2432, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24069487